Document center

Cancer Imaging Initiative - Commission Factsheet

Published on | 2 years ago

Programmes Health Missions

The European Cancer Imaging Initiative is one of the flagships of the Europe's Beating Cancer Plan (EBCP). One of the objectives of the Plan is to make the most of the potential of data and digital technologies such as Artificial Intelligence (AI) or High-Performance Computing (HPC) to combat cancer.  

The aim of the European Cancer Imaging Initiative is to foster innovation and deployment of digital technologies in cancer treatment and care, to achieve more precise and faster clinical decision-making, diagnostics, treatments and predictive medicine for cancer patients

The Initiative will showcase how medical images can be accessed, used and pooled, while ensuring a high level of ethics, trust, security and personal data protection in full compliance with EU values and rules. It will make large amounts of cancer images and linked clinical data easily accessible to European clinicians, researchers and innovators in line with the European data strategy and supporting the goals of the European Health Data Space. 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.